SCHEMBL6496489

SCHEMBL6496489

COc1ccc(-c2cc(N)nc(S)n2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
HSD17B10 Q99714 2/20 0.50
HTT P42858 2/20 0.50
USP2 O75604 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.50
AGTR1 P30556 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
MAPT P10636 3/20 0.47
ACACA Q13085 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
DYRK1A Q13627 1/20 0.46
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1388381 0.84 DYRK1A (0.66) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7708794 0.80 KDM4E (0.54) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6504950 0.76 KDM4E (0.48) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL3617027 0.74 KDM4E (0.46) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL1752782 0.72 ALDH1A1 (0.50) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL30268387 0.72 PFKFB3 (0.50) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6749872 0.72 HSP90AA1 (0.61) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL427925 0.71 MEN1 (0.75) KDM4EALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6703514 0.71 ALOX5AP (0.52) KDM4EALDH1A1HSD17B10MAPTACACA
SCHEMBL17144996 0.71 KDM4E (0.65) KDM4EALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911443-B2 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-06-28 US disclosed
EP-1278750-B1 IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-08-04 EP disclosed
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054179-A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives XRCC6, XRN2, HRH2 KDM4E 1134/4885ALDH1A1 2402/4885MEN1 3675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.